230 results
424B5
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Prospectus supplement for primary offering
4:32pm
Injury: Evaluation of a Novel Device) clinical study to evaluate the safety and utility of a novel spinal cord delivery device to administer OPC1 … .
OPC1, an allogeneic oligodendrocyte progenitor cell therapy which will be evaluated in the DOSED clinical study, to test the safety and utility
8-K
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Entry into a Material Definitive Agreement
4:15pm
the safety and utility of a novel spinal cord delivery device to administer OPC1 to the spinal parenchyma in SCI patients. Per the correspondence
8-K
EX-1.1
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Entry into a Material Definitive Agreement
4:15pm
laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or toxic … , conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, “dear healthcare provider” letter, or other notice
424B5
xapjwo scw
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-99.1
9v9xkd8
11 Aug 22
LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm
8-K
EX-10.1
4nqcffoeav0d
7 Jul 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
b0txxwfi1a36by0t
12 May 22
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm
8-K
EX-99.1
c3701q3ln1f 7r
11 May 22
Regulation FD Disclosure
7:54pm
8-K
4d3fzp
11 May 22
Regulation FD Disclosure
7:54pm